<DOC>
	<DOCNO>NCT00325546</DOCNO>
	<brief_summary>Primary : effect weight loss weight maintenance 9 month prescribe hypocaloric diet obese patient . Secondary : effect HDL-Cholesterol , triglyceride , fasting-insulin , fast glucose , waist circumference - safety tolerability</brief_summary>
	<brief_title>Study Weight-Reducing Effect Safety Rimonabant In Obesity ASIA ( RIO-ASIA )</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Body mass index ( BMI ) &gt; 25 kg/mÂ² Absence stable weight ( variation &lt; 5 kg ) within three month prior screen visit ) , Absence effective contraceptive method female childbearing potential , Presence treat untreated type 1 type 2 diabetes , Systolic blood pressure &gt; 165 mm Hg and/or diastolic blood pressure &gt; 105 mm Hg 2 consecutive visit screen inclusion visit , Presence secondary hypertension , Patients conditions/concomitant disease make non evaluable primary efficacy endpoint ( presence clinically significant endocrine disease accord Investigator , obesity know endocrine origin ... ) Presence severe medical psychological condition chronic conditions/infections opinion Investigator would compromise patient 's safety successful participation study , Presence clinically significant abnormality accord Investigator ECG perform inclusion visit . Presence history cancer within past five year exception adequately treat localized basal cell skin cancer situ uterine cervical cancer . Related previous concomitant medication : Drugs affect weight ( e.g. , sibutramine , orlistat , herbal preparation , etc ) . Antidiabetic drug . Related laboratory finding : Positive test hepatitis B surface antigen and/or hepatitis C antibody . Abnormal TSH level ( TSH &gt; ULN &lt; LLN ) . Positive urine pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Obesity</keyword>
</DOC>